NeoGenomics Launches PanTracer Pro for Advanced Solid Tumor Testing
NeoGenomics has introduced PanTracer Pro, a molecular testing solution combining comprehensive genomic profiling with diagnosis-directed assays for advanced solid tumors, designed to streamline biomarker assessment and support faster treatment decisions.
NeoGenomics, Inc. has announced the availability of PanTracer Pro, a new addition to the PanTracer Family designed to help clinicians navigate increasingly complex molecular testing workflows to make informed decisions for patients with advanced-stage solid tumors. The new diagnostic solution combines broad genomic profiling and customized diagnostic testing into a single order with a focus on faster turnaround times.
PanTracer Pro integrates broad, comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing selected based on tumor type. By delivering comprehensive, guideline-aligned insights through a single coordinated order, PanTracer Pro enables physicians to ensure relevant biomarkers are assessed upfront rather than through multiple, sequential tests. Turnaround time for the test is 8-10 days, supporting timely real-world treatment decisions.
The offering is designed to address fragmented testing workflows, treatment delays, and incomplete biomarker assessment in cancer care. As precision oncology continues to evolve, clinicians face growing diagnostic complexity, increasing biomarker requirements, and mounting pressure to initiate treatment quickly, often before a complete molecular profile is available. Fragmented testing workflows, sequential ordering, and tissue limitations can delay care and introduce uncertainty at critical decision points.
The ability of PanTracer Pro to combine broad DNA and RNA sequencing across more than 500 cancer-related genes with tumor-specific ancillary testing supports therapy selection, helps identify potential clinical trial options, and facilitates personalized treatment planning based on a patient's unique tumor biology. Beyond streamlining test selection, PanTracer Pro may help identify clinically relevant biomarkers that can be missed with incomplete testing.
When tissue samples are insufficient or unavailable, cases can automatically reflex to PanTracer LBx, NeoGenomics' pan-solid tumor liquid biopsy assay, allowing clinicians to continue diagnostic workup without restarting the process.
The chief executive officer at NeoGenomics stated that every delay or unanswered question in the diagnostic process can affect how quickly patients begin treatment, and that PanTracer Pro is designed to help clinicians get the information they need earlier and more reliably, so care teams can plan next steps with greater clarity and confidence across the care journey.
NeoGenomics, trading at $11.38, has seen mixed share price performance, with a 30 day return of an 11.0% decline and a 1 year return of a 21.1% decline. Over a 5 year span, the stock shows a 79.9% decline. The company is currently loss making, with a net income margin of 16.0% in the red. NeoGenomics posted recent annual revenue growth of 8.86%.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom.